CN113507932B - 3-o-氨基磺酸-16,16-二甲基-d-高马萘雌甾酮在治疗肿瘤疾病中的用途 - Google Patents

3-o-氨基磺酸-16,16-二甲基-d-高马萘雌甾酮在治疗肿瘤疾病中的用途 Download PDF

Info

Publication number
CN113507932B
CN113507932B CN201980088362.1A CN201980088362A CN113507932B CN 113507932 B CN113507932 B CN 113507932B CN 201980088362 A CN201980088362 A CN 201980088362A CN 113507932 B CN113507932 B CN 113507932B
Authority
CN
China
Prior art keywords
average
drug
tumor
treatment
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980088362.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113507932A (zh
Inventor
沙米尔·肖诺维奇·伊利亚索夫
亚历山大·格里戈里耶维奇·沙夫瓦
斯韦特兰娜·尼古拉耶芙娜·莫罗兹基娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natalia Eduardorfna Eliassova
Original Assignee
Natalia Eduardorfna Eliassova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natalia Eduardorfna Eliassova filed Critical Natalia Eduardorfna Eliassova
Publication of CN113507932A publication Critical patent/CN113507932A/zh
Application granted granted Critical
Publication of CN113507932B publication Critical patent/CN113507932B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980088362.1A 2018-11-08 2019-09-19 3-o-氨基磺酸-16,16-二甲基-d-高马萘雌甾酮在治疗肿瘤疾病中的用途 Active CN113507932B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018139336 2018-11-08
RU2018139336A RU2680603C1 (ru) 2018-11-08 2018-11-08 Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний
PCT/RU2019/000650 WO2020096486A1 (fr) 2018-11-08 2019-09-19 Utilisation de 3-o-sulfamate 16,16-diméthyl-d-homequilenine pour traiter des maladies cancéreuses

Publications (2)

Publication Number Publication Date
CN113507932A CN113507932A (zh) 2021-10-15
CN113507932B true CN113507932B (zh) 2025-02-18

Family

ID=65479433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088362.1A Active CN113507932B (zh) 2018-11-08 2019-09-19 3-o-氨基磺酸-16,16-二甲基-d-高马萘雌甾酮在治疗肿瘤疾病中的用途

Country Status (6)

Country Link
US (1) US20220105058A1 (fr)
EP (1) EP3878454A4 (fr)
CN (1) CN113507932B (fr)
EA (1) EA202191323A1 (fr)
RU (1) RU2680603C1 (fr)
WO (1) WO2020096486A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2755250C1 (ru) * 2021-01-21 2021-09-14 Ильясова Наталья Эдуардовна Препарат на основе стероидных эстрогенов для лечения эндометриоза
RU2752064C1 (ru) * 2021-02-02 2021-07-22 Ильясова Наталья Эдуардовна Новый способ синтеза 3-о-сульфамата 16,16-диметил-d-гомоэквиленина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60022517T2 (de) * 1999-07-15 2006-08-03 Kobenhavns Universitet Zusammensetzung mit steoridisher östrogen wirkung ohne steigerung des brustkrebsrisikos
DE10307103A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate
CN101129353B (zh) * 2007-09-17 2010-04-14 北京珅奥基医药科技有限公司 7-羟基-3-[(4-羟基)-3-(3-甲基-丁基-2-烯基)苯基]-4h-1-苯并吡喃-4-酮的用途
CN101199509B (zh) * 2007-10-31 2010-11-03 北京珅奥基医药科技有限公司 2",2"-二甲基-2"h,4h-3,6"-二苯并吡喃-4-酮在制备抗肿瘤药物中的用途
KR102337598B1 (ko) * 2013-05-03 2021-12-10 신닥스 파마슈티컬스, 인크. 암 치료 방법
KR101819544B1 (ko) * 2016-11-25 2018-01-17 애니젠 주식회사 5'-하이드록시-5-니트로-인디루빈-3'-옥심을 유효 성분으로 함유하는 유방암 치료제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gluzdikov Ivan Alexandrovich.Sintez ingibitorov sulfatazy estrona:Avtoref.disp.na soiskanie uchenoi steperi kandidata khimicheskikh nauk..2017,1-17. *

Also Published As

Publication number Publication date
RU2680603C1 (ru) 2019-02-25
US20220105058A1 (en) 2022-04-07
CN113507932A (zh) 2021-10-15
EA202191323A1 (ru) 2021-08-06
EP3878454A4 (fr) 2022-08-24
WO2020096486A1 (fr) 2020-05-14
EP3878454A1 (fr) 2021-09-15

Similar Documents

Publication Publication Date Title
Chen et al. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways
CN1315479C (zh) 橄榄苦苷在制备抑制血管生成药物中的用途
TW200932245A (en) Methods and compositions for inhibiting angiogenesis
CN104027339B (zh) 一种维生素组合物及其调理卵巢功能应用
EP4119557A1 (fr) Combinaison pharmaceutique comprenant un composé pyridino[1,2-a]pyrimidinone
CN113507932B (zh) 3-o-氨基磺酸-16,16-二甲基-d-高马萘雌甾酮在治疗肿瘤疾病中的用途
MX2009001163A (es) Metodos y composiciones para promover la actividad de terapias anticancer.
Li et al. A011, a novel small-molecule ligand of σ2 receptor, potently suppresses breast cancer progression via endoplasmic reticulum stress and autophagy
WO2024017316A1 (fr) Produit pharmaceutique de polythérapie et polythérapie
US20100144652A1 (en) Composition comprising a glycolytic inhibitor and a ring system comprising a sulphamate group for the treatment of cancer
CN114007624B (zh) 3-氧-氨磺酰氧基-7β-甲基-D-增-6-氧杂雌-1,3,5(10),8(9)-四烯-17a-酮用于治疗乳腺癌的用途
KR20130051361A (ko) 황금 찰수수 추출물을 유효성분으로 포함하는 암 질환 예방 및 치료용 조성물
CN112370446A (zh) Egcg药物组合物及其制备方法和在卵巢功能保护中的应用
US20190022111A1 (en) ESTROGEN RECEPTOR Beta PARTIAL AGONIST HAVING ESTROGEN RECEPTOR Alpha INHIBITORY EFFECT, AND GYNECOLOGICAL DISEASE THERAPEUTIC AGENT USING SAME
WO2006110299A1 (fr) Compositions de 3,3'-diindolylmethane inhibant l’angiogenese
EP3878453A1 (fr) Traitement du cancer du sein, y compris la forme triplement négative
EA044450B1 (ru) Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний
CN116077512A (zh) 曼那斯汀减轻化疗药物顺铂导致的多器官损伤的应用
Brown et al. Breast tumors in patients with hyperprolactinemia
CN109350620B (zh) 一种治疗卵巢癌的药物及其用途
US20210060013A1 (en) Method for Preventing Triple Negative Breast Cancer in Predisposed Subjects
EA042238B1 (ru) ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-7β-МЕТИЛ-D-ГОМО-6-ОКСАЭСТРА-1,3,5(10),8(9)-ТЕТРАЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EA042485B1 (ru) Лечение рака молочной железы, включая трижды негативную форму
WO2020199973A1 (fr) UTILISATION COMBINÉE D'UN MÉDICAMENT COMPOSÉ A-NOR-5α ANDROSTANE ET D'UN MÉDICAMENT ANTI-CANCÉREUX
CN103800299A (zh) 一种醋酸甲羟孕酮片及其制备工艺

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant